This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ritchie, J. L. Articles by Kennedy, J. W. Search for Related Content PubMed PubMed Citation Articles by Ritchie, J. L. Articles by Kennedy, J. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Attack Hazardous Substances DB THALLIUM, ELEMENTAL

Circulation, Vol 70, 867-875, Copyright © 1984 by American Heart Association

ARTICLES

Global and regional left ventricular function and tomographic radionuclide perfusion: the Western Washington Intracoronary Streptokinase In Myocardial Infarction Trial

JL Ritchie, KB Davis, DL Williams, J Caldwell and JW Kennedy

The Western Washington Intracoronary Streptokinase In Myocardial Infarction Trial enrolled 250 patients with acute myocardial infarction. After the coronary angiographic diagnosis of thrombosis, patients were randomly assigned to receive either conventional therapy with heparin or intracoronary streptokinase followed by heparin. Of the 232 patients who survived at least 60 days, 207 (89%) underwent radionuclide ventriculographic determination of global and regional ejection fraction at a single institution at 62 +/- 35 days after infarction. In the first 100 patients, infarct size was also determined by quantitative single-photon emission tomographic imaging with thallium-201 (201Tl) and expressed as a percentage of the left ventricle with a perfusion defect. Overall, global ejection fraction did not differ between patients treated with streptokinase (45.9 +/- 13.9%; n = 115) and control patients (46.1 +/- 14.4%; n = 92, p = NS). Similarly, the regional posterolateral, inferior, and anteroseptal ejection fraction did not differ between the two groups. Infarct size as measured by 201Tl tomography was 19.4 +/- 12.8% (n = 52) of the left ventricle for the streptokinase group and 19.6 +/- 11.8% (n = 48; p = NS) for the control group. When patients were compared within groups by electrocardiographic location of infarction, time to treatment, or the presence or absence of vessel opening, there were no significant differences between streptokinase and control patients. Statistical inclusion of the 18 patients who died early and were unavailable for study also failed to modify the results, except for a possible reduction in inferior infarct size as measured by 201Tl tomography.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				P. Pascale, P. Taffe, C. Regamey, L. Kappenberger, and M. Fromer Reduced Ejection Fraction After Myocardial Infarction: Is It Sufficient To Justify Implantation of a Defibrillator? Chest, October 1, 2005; 128(4): 2626 - 2632. [Abstract] [Full Text] [PDF]

				J. C. Silva, C. E. Rochitte, J. S. Junior, J. Tsutsui, J. Andrade, E. E. Martinez, P. J. Moffa, J. C. Menegheti, R. Kalil-Filho, J. F. Ramires, et al. Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging Eur. Heart J., January 1, 2005; 26(1): 36 - 43. [Abstract] [Full Text] [PDF]

				G. Ndrepepa, A. Kastrati, F.-J. Neumann, C. Schmitt, J. Mehilli, and A. Schomig Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting Eur. Heart J., September 2, 2004; 25(18): 1635 - 1640. [Abstract] [Full Text] [PDF]

				V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF]

				U. Sechtem Imaging myocardial area at risk and final infarct size Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C36 - C46. [PDF]

				E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119(1_suppl): 253S - 277S. [Full Text] [PDF]

				H Sasao, K Tsuchihashi, M Hase, T Nakata, K Shimamoto, and t. N.-9. investigators Does primary stenting preserve cardiac function in myocardial infarction? A case-control study Heart, November 1, 2000; 84(5): 515 - 521. [Abstract] [Full Text]

				F. K. Welty, M. A. Mittleman, S. M. Lewis, W. L. Kowalker, R. W. Healy, S. J. Shubrooks Jr, and J. E. Muller A Patent Infarct-Related Artery Is Associated With Reduced Long-term Mortality After Percutaneous Transluminal Coronary Angioplasty for Postinfarction Ischemia and an Ejection Fraction <50% Circulation, April 15, 1996; 93(8): 1496 - 1501. [Abstract] [Full Text]

				D. W. Krichbaum and D. A. Trivedi Thrombolytic Therapy in Acute Myocardial Infarction Journal of Pharmacy Practice, January 1, 1990; 3(5): 332 - 348. [PDF]